Corporate Spotlight

Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA

19 July 2021 – Corporate Spotlight | Gabrielle Wermenbol joins Telix as Chief Financial Officer, Europe, Middle East & Africa (EMEA)

Telix is delighted to announce the appointment of Gabrielle Wermenbol as Chief Financial Officer, Europe, Middle East and Africa (EMEA).

Gabrielle brings with her over 20 years’ experience in life sciences, pharmaceutical and consumer goods businesses, and has held executive positions with companies including Johnson & Johnson, medical devices company, Terumo Europe, and Pfizer’s animal health spin-off, Zoetis, where she also served as a Board member.

She has a Master’s degree in Applied Economic Sciences from the University of Antwerp, Belgium, along with an MBA from Xavier’s Institute of Management in Orissa, India.

With widespread experience in business transformation and team building, Gabrielle is the ideal fit to lead Telix’s financial operations in EMEA as we prepare for the commercial launch of our lead product Illuccix® for prostate cancer imaging.

On joining Telix, Gabrielle stated, “I am very excited to start my new challenge at Telix and look forward to working with the team to support the company in the transition to commercialisation and revenue generation. Telix is full of potential with a comprehensive late stage portfolio to both diagnose and treat different types of cancer and make a difference in patients’ lives for the better, and I am proud to be part of that journey.

We welcome Gabrielle to the Telix team, as we work to deliver on our mission to help patients with cancer live longer, better quality lives.

To return to our home page please click here.

More Articles

ASX News

Telix Seneffe Production Facility: Progress Update

Melbourne (Australia) and Seneffe (Belgium) – 30 July 2021. Telix authorised to decommission first of two cyclotrons at Seneffe radiopharmaceutical...

ASX News

Activities Report and Appendix 4C for June 2021 Quarter

Melbourne (Australia) – 22 July 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June...

ASX News

ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update

Melbourne (Australia) – 20 July 2021. Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer...

Corporate Spotlight

Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA

19 July 2021 – Corporate Spotlight | Gabrielle Wermenbol joins Telix as Chief Financial Officer, Europe, Middle East & Africa...

Corporate Spotlight

Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations

Melbourne (Australia) – 12 July 2021. Telix announces that Ms. Kyahn Williamson has joined the Telix executive leadership team in...

ASX News

First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

Melbourne (Australia) – 23 June 2021. Telix announces that a first patient has been dosed in a Phase I study...

ASX News

IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update

Melbourne (Australia) – 21 June 2021. Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on...

ASX News

Telix Update on FDA New Drug Application Review for Illuccix®

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 17 June 2021. Telix announces participation in a late-cycle meeting with the U.S....

Corporate Spotlight

Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research

MELBOURNE, Australia and INDIANAPOLIS 14 June, 2021 – Telix announces the launch of a new educational platform focused on radiopharmaceutical...

Corporate Spotlight

Telix launches “Gallium Wave” Awareness Website

Melbourne (Australia) and Indianapolis (U.S.A.) – 11 June 2021. Telix announces the launch of a new website “Gallium Wave”, as...

Corporate Spotlight

Scott Law joins Telix as SVP Global Manufacturing Operations

11 June 2021 – Corporate Spotlight | Scott Law joins Telix as Senior Vice President Global Manufacturing Operations

ASX News

Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy

Liège (Belgium) and Gothenburg (Sweden) – 7 June 2021. Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of...